Smile-on News Logo

Smile-on News

Healthcare Learning Logo

Medical pioneer receives honorary fellowship

16 July 2015

Medical pioneer receives honorary fellowship

A pioneer who was heavily involved in the development of new medicines for the treatment of cancer, arthritis, diabetes and Alzheimer’s disease has received an Honorary Fellowship from the University of Wales Trinity Saint David.

Professor Christopher Wood was born in Cardiff and began his medical career as a surgeon specialising in cancer surgery. He qualified from the Welsh National School of Medicine in Cardiff and has an MD degree from the University of Wales. He was also a Fellow of the Royal College of Surgeons of Edinburgh and became a consultant surgeon at the Royal Postgraduate Medical School in London. He was appointed honorary Professor at Imperial College, London in 2008.

He has published extensively on surgical and cancer-related topics throughout his career and, in recent years, has focused on the development of new medicines. This led to the approval of the first new drug in thirty years for the treatment of childhood leukaemia in 2004. Currently, he is working on the development of new medicines for the treatment of cancer, arthritis, diabetes and Alzheimer’s disease.

As well as being passionate about medicine, Professor’s Wood other love is music. He is a keen composer and a strong supporter of the arts, with a special emphasis on choral music and encouraging young talented musicians as well as being chairman of the Council of Trustees for the Royal College of Organists.

Professor Wood commented: “I thank the University for the privilege of being able to accept the honour that has been bestowed upon me. I am bemused that I should be honoured for indulging my passion in medicine and music and doing something that I have thoroughly enjoyed every single day of my life.

“One of the privileges I have had in my career was being able to develop new cancer drugs and there is no substitute for being able to bring joy into the life of someone who is suffering from cancer, and to give them the news that they have responded to treatment and that they are doing well.

“I was very fortunate in being able to develop the first new drug for childhood leukaemia in over thirty years. That drug became approved in Europe through studies that were done here in Wales.”

comments powered by Disqus


This month's special feature is:

BDA Conference Spotlight


Sign up to our newsletter